Clinical trial
Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Immunogenicity of F61 Injection After a Single Dose in Healthy Chinese Subjects
NCT05483504 is registered in ClinicalTrials.gov with Wuhan Institute of Biological Products Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Immunogenicity of F61 Injection After a Single Dose in Healthy Chinese Subjects
- Lead sponsor
- Wuhan Institute of Biological Products Co., Ltd
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- August 31, 2022
- Completion date
- December 31, 2023
- Enrollment
- 40 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.